Accuracy of Diamond-Forrester estimates for CAD declining, says JAMA study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-03-22 22:00 GMT | Update On 2021-03-23 07:54 GMT

USA: The accuracy of Diamond-Forrester estimates of pretest probability of coronary artery disease (CAD) are declining, according to the authors view point, published in the journal JAMA Internal Medicine.

According to the authors, the European CAD Consortium estimation method is the most reliable.

The Diamond-Forrester estimates were developed in the late 1970s based on a small group of highly selected patients, most of whom were men with an average age <50 years. Since then, the epidemiology of CAD has changed considerably. Now, the patients tend to be older and there are more women.

The consortium estimates are based on data for 2260 patients from 14 catheterization laboratories and yield better classification of women, usually downward relative to Diamond-Forrester classification.

A 2019 study that compared various risk scores found that the CAD Consortium clinical score performed best among the 3 options (updated Diamond-Forrester, CONFIRM risk score, consortium score), although not perfectly.

This view point by Raymond J. Gibbons and Todd D. Miller from Mayo Clinic, Rochester, Minnesota, summarizes their assessment of the evidence for a temporal decline in the accuracy of Diamond-Forrester estimates, indicates which current method for ePTP is most reliable, and explains why ePTP remains clinically useful.

Key points:

The authors endorse consortium estimates as most reliable and say adding more risk factors "does not seem justified."
Use of consortium estimates means clinicians also have to reconsider how they evaluate CAD in women, who have less obstructive disease when younger than 70 years.
The estimate also can predict outcomes, the authors write—specifically myocardial infarction and death—but this applicability is underappreciated.
They conclude that because CAD is decreasing, less testing overall is warranted.
Estimates <15%, they say, do not require cardiac testing, in keeping with 2019 European Society of Cardiology guidelines.

Reference:

"Declining Accuracy of the Traditional Diamond-Forrester Estimates of Pretest Probability of Coronary Artery Disease: Time for New Methods," is published in the journal JAMA Internal Medicine.

DOI: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2777340

Article Source : JAMA Internal Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Accuracy of Diamond-Forrester estimates for CAD declining, says JAMA study

Similar News

Pneumococcal polysaccharide vaccine Found Ineffective in Reducing Cardiovascular Events, reports JAMA

Deep learning model helps in identifying the risk of complete heart block, finds JAMA

Living in a food desert doubles stroke risk for patients with atrial fibrillation, study finds

Regular Exercise After Weight Loss Outperforms GLP-1 Drugs in Reducing MI and Stroke Risk, suggests study

Cardiovascular Risk Highest in Mothers with Hypertension, Diabetes, or Both: Study

Periodontitis Treatment Reduces Carotid Intima-Media Thickness Over 2 Years: Study Shows

FDA Approves Bumetanide Nasal Spray for Edema in Heart, Liver, and Kidney Disease

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits